[go: up one dir, main page]

AP2013006939A0 - A drug delivery device - Google Patents

A drug delivery device

Info

Publication number
AP2013006939A0
AP2013006939A0 AP2013006939A AP2013006939A AP2013006939A0 AP 2013006939 A0 AP2013006939 A0 AP 2013006939A0 AP 2013006939 A AP2013006939 A AP 2013006939A AP 2013006939 A AP2013006939 A AP 2013006939A AP 2013006939 A0 AP2013006939 A0 AP 2013006939A0
Authority
AP
ARIPO
Prior art keywords
delivery device
drug delivery
drug
delivery
Prior art date
Application number
AP2013006939A
Other languages
English (en)
Inventor
Toit Lisa Du
Viness Pillay
Yahya Essop Choonara
Original Assignee
Univ Witwatersrand Jhb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Witwatersrand Jhb filed Critical Univ Witwatersrand Jhb
Publication of AP2013006939A0 publication Critical patent/AP2013006939A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AP2013006939A 2010-11-26 2011-11-28 A drug delivery device AP2013006939A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA201003748 2010-11-26
PCT/IB2011/055328 WO2012070027A1 (en) 2010-11-26 2011-11-28 A drug delivery device

Publications (1)

Publication Number Publication Date
AP2013006939A0 true AP2013006939A0 (en) 2013-06-30

Family

ID=46145443

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013006939A AP2013006939A0 (en) 2010-11-26 2011-11-28 A drug delivery device

Country Status (6)

Country Link
US (1) US20140023692A1 (xx)
EP (1) EP2643020A4 (xx)
CN (1) CN103429266A (xx)
AP (1) AP2013006939A0 (xx)
BR (1) BR112013013123A2 (xx)
WO (1) WO2012070027A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
MX337286B (es) 2007-05-25 2016-02-22 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9782345B2 (en) 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CN107106720B (zh) * 2014-06-05 2020-06-16 约翰内斯堡威特沃特斯兰德大学 一种伤口敷料
DE102014012675A1 (de) * 2014-08-26 2016-03-03 Wavelight Gmbh Vernetzung von Augengewebe
EP3616120B1 (en) 2017-04-27 2024-09-04 Retinascan Limited System and method for automated funduscopic image analysis
AU2019252676A1 (en) * 2018-04-11 2020-11-26 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
KR102176486B1 (ko) * 2019-06-14 2020-11-10 동국대학교 산학협력단 히알루론산 기반의 안과용 약물전달체의 제조방법
CN114577983B (zh) * 2022-01-26 2024-08-16 西安卓恰新材料科技有限公司 体外降解实验的实验方法及实验装置
CN116392648B (zh) * 2023-04-14 2024-08-23 中国科学院长春应用化学研究所 一种温度、炎症双响应性的抗凝复合涂层及其制备方法、应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0874643B1 (en) * 1996-02-15 2001-11-21 J. Paul Santerre Bioresponsive pharmacologically-active polymers and articles made therefrom
US6060534A (en) * 1996-07-11 2000-05-09 Scimed Life Systems, Inc. Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties
US20040253293A1 (en) * 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
US20050129731A1 (en) * 2003-11-03 2005-06-16 Roland Horres Biocompatible, biostable coating of medical surfaces
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
AU2005244848A1 (en) * 2004-05-12 2005-12-01 Medivas, Llc Wound healing polymer compositions and methods for use thereof
CN100346847C (zh) * 2005-03-15 2007-11-07 北京扶泰敏德医药技术有限公司 具有双期或多期释放速率的医用涂层系统及其应用
ES2717607T3 (es) * 2006-03-31 2019-06-24 Mati Therapeutics Inc Estructuras de administración de fármacos y composiciones para el sistema nasolagrimal
JP5694664B2 (ja) * 2006-09-29 2015-04-01 サーモディクス,インコーポレイティド 生分解性眼用インプラント及び眼の病気を治療する方法
EP2299986A1 (en) * 2008-06-19 2011-03-30 University Of The Witwatersrand, Johannesburg A chronotherapeutic pharmaceutical dosage form

Also Published As

Publication number Publication date
CN103429266A (zh) 2013-12-04
BR112013013123A2 (pt) 2018-06-19
EP2643020A1 (en) 2013-10-02
EP2643020A4 (en) 2014-11-12
WO2012070027A1 (en) 2012-05-31
US20140023692A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
GB2479953B (en) Drug delivery device
HK1179542A1 (zh) 藥物遞送裝置
SG10201503939SA (en) Drug delivery device
IL220003A0 (en) A drug delivery device
IL228696A0 (en) Combines drug release device and drug release device
IL221134A (en) A drug release device assembly and a drug release device containing it
HK1181337A1 (en) Electro-mechanical drug delivery device
ZA201302588B (en) Medicament delivery device
PL2640450T3 (pl) Urządzenia do podawania leku
HK1166731A1 (en) Drug delivery device
HK1210068A1 (en) A drug delivery device
IL218839A0 (en) Drug delivery device
IL215219A0 (en) Drug delivery device
HK1166728A1 (en) Drug delivery device
EP2589370A4 (en) DEVICE FOR DISTRIBUTING MEDICAMENTS
AP2013006939A0 (en) A drug delivery device
ZA201106668B (en) Zoo-technical drug delivery device
EP2506909A4 (en) ACTIVE RELEASE DEVICE
ZA201306604B (en) Drug delivery device
IL217416A0 (en) Drug delivery delivery device
ZA201208185B (en) Intravaginall drug delivery device
GB2485273B (en) Medicinal delivery device
EP2547384A4 (en) DEVICE FOR DELIVERY OF MEDICATION WITH GAS PRESSURE
EP2560711A4 (en) DEVICE FOR DELIVERY OF MEDICAMENT
EP2626055A4 (en) ACTIVE RELEASE DEVICE